Intravesical bacillus Calmette-Guérin (BCG) remains the cornerstone of treatment for high-risk non–muscle-invasive bladder cancer (NMIBC). Despite decades ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
Non-muscle-invasive bladder cancer (NMIBC) has a high risk of recurrence and progression among patients without adequate Bacillus Calmette-Guérin.
Flaig: It has been a remarkable 10 years for bladder cancer. If you think back to 10 or 15 years ago, we had no new ...
A research team is shedding new light on Bacillus Calmette-Guerin (BCG), a decades-old bladder cancer treatment, which is also given as vaccine against tuberculosis. The findings could help improve ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
Hosted on MSN
Bladder cancer treatment reprograms bone marrow to boost immune system's cancer-fighting ability
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results